Projet BIO-MICRO (Horizon Europe, appel à projets 2024)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

European micronutrient (MN) guidelines explicitly recommend to replete any MN deficiency in critically ill patients. MNs are crucial for immune defence, cellular metabolism and as antioxidant. Critically ill patients have increased requirements for MNs which can result in severe deficiencies and worse clinical outcomes. There are currently no accurate methods to diagnose MN deficiencies in critically ill patients. MN plasma concentrations are substantially affected by inflammation. MN concentrations in erythrocytes and leukocytes or new functional markers may better reflect real deficiencies. Furthermore, most intervention trials with high-dose MN monotherapy yielded mixed results on clinical outcomes. Due to the absence of accurate monitoring tools of MN body status, all patients received fixed high-dose MN monotherapy. Personalized MN therapy based on subphenotyping of patients and accurate estimation of individual metabolic demands in all phases of disease may yield better outcome than this one-size-fits-all strategy. In addition, more insight in the complex interplay between MNs and the role of MNs in post-ICU phase is necessary to guide future trials. BIO-MICRO consists of physicians, biologists, methodologists, trialists, health scientists, clinical chemists, patient representatives and industrial participants and aims to train innovative research fellows with interdisciplinary and intersectoral skills to develop the urgently needed strategies for MN personalized therapy in critically ill patients. They will develop new analytics for reliably determination MN body status, investigate subphenotypes of patients likely to benefit from MN therapy, enable guidance with appropriate timing of MN therapy, investigate the interplay between MNs and explore the role of MNs in the rehabilitation phase. This will ultimately lead to significantly decreased mortality and organ dysfunctions, shorter ICU stay, improvement of quality of life and significant cost reductions.

Mots clés : micronutrients, personalized medicine, biomarkers, inflammation, redox status, oxidative stress

Participants :
- Dewolfpact b.v. (Pays-Bas) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Randox teoranta (Irlande) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 682174.08 €
- Université libre d'Amsterdam (Pays-Bas) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Diagnotix bv (Pays-Bas) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Wageningen University & Research (Pays-Bas) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Leibniz-Gemeinschaft (Allemagne) — Partner, beneficiary, Recherche, subvention : 290272.32 €
- Amsterdam University Medical Centers (Pays-Bas) — Coordinator, beneficiary, Recherche, subvention : 610571.52 €
- Université de Potsdam (Allemagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Universitätsklinikum Würzburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 290272.32 €
- Reiner haga medisch diagnostisch centrum bv (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 305285.76 €
- Hôpital universitaire de la Charité de Berlin (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 580544.64 €
- Ziekenhuis Gelderse Vallei (Pays-Bas) — Partner, beneficiary, Autres, subvention : 305285.76 €
- Stichting martini ziekenhuis (Pays-Bas) — Partner, beneficiary, Autres, subvention : 305285.76 €
- Université de Foggia (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 563510.16 €